Rationale: b 2 -Agonists are the treatment of choice for exerciseinduced bronchoconstriction (EIB) and act through specific receptors (ADRB2). Arg16Gly polymorphisms have been shown to affect responses to regular use of b 2 -agonists. Objectives: To evaluate the influence of the Arg16Gly receptor polymorphism on salmeterol bronchoprotection in EIB and assess predictors of bronchoprotection. Methods: A prospective, genotype-blinded, randomized trial was performed in 26 subjects (12 Arg16Arg and 14 Gly16Gly) with EIB who were not on controller therapy. Subjects were administered salmeterol, 50 mg twice a day for 2 weeks, and underwent an exercise challenge 9 hours after the first and last drug dose. In addition to genotype, FEV 1 , response to salmeterol, degree of EIB, and exhaled nitric oxide (FE NO ) at baseline were examined for their association with loss of bronchoprotection (LOB). Measurements and Main Results:The maximum exercise-induced FEV 1 fall was 27.9 6 1.4% during the run-in period, 8.1 6 1.2% (70.3 6 4.1% bronchoprotection) after the first salmeterol dose, and 22.8 6 3.2% (18.9 6 11.5% bronchoprotection) after 2 weeks of salmeterol (P ¼ 0.0001). The Arg16Gly polymorphisms were not associated with the LOB in response to salmeterol. FE NO values at baseline were significantly related to the LOB (r ¼ 0.47; P ¼ 0.01). Mean change was a 74 6 13% LOB in subjects with FE NO levels greater than 50 ppb and a 7 6 16% gain in bronchoprotection in those with FE NO levels less than 25 ppb (P ¼ 0.01). Conclusions:The LOB that occurs with chronic long-acting b 2 -agonists use is not affected by ADRB2 Arg16Gly polymorphisms. High FE NO was associated with marked LOB. Use of long-acting b 2 -agonists before achieving a reduction in FE NO may need to be avoided. Clinical trial registered with www.clinicaltrials.gov (NCT 00595361).Keywords: asthma; b 2 -agonist; nitric oxide; pharmacogenetics; tolerance Inhaled b 2 -adrenergic agonists are widely used and have been proved to be the most effective treatment available to acutely prevent and reverse the bronchial obstruction that occurs after physical activity (1). Both short-acting and long-acting b 2 -agonists (SABA and LABA) administered in a standard dose immediately before exercise have been shown to reduce the fall in FEV 1 by 70-80% most subjects (2).However, daily treatment may lead to tolerance to the bronchoprotective effect (3). This effect has been documented in response to direct (methacholine and adenosine monophosphate [AMP]) (4) and indirect (allergen and exercise) stimuli (5, 6), occurring as early as 7 days after regular use and even in the face of concomitant use of inhaled corticosteroids (ICS) (3). The loss of bronchoprotection (LOB) has been reported to range from 49% to 72% of the initial observed effect (3) with some subjects retaining near complete bronchoprotection and others developing a paradoxical increase in bronchoconstriction to the provocative stimulus.It has been speculated this phenomenon may be caused by receptor down-regulation, redu...
Derrida saw laughter as a version of aporia; and he linked aporia to an undecidability that he ties to fiction. I argue that such undecidability contributes to some jokes. Sometimes this undecidability enables the joke to combine plausibility and delightfulness. More interesting and more aporetic is the way that undecidability contributes to jokes that foreground their textual status (some meta-jokes for instance) and those that have an effect of unfathomability. The jokes considered include one on which Derrida commented and another which was told at his Columbia University memorial service.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.